Voxelotor and Red Blood Cell Pyruvate Kinase Activator Affect Clot Strength in Sickle Cell Disease

• Published in: Blood Vol. 142; no. Supplement 1; p. 1114
• Main Authors: Sekyonda, Zoe, Abonga, Calvin, Delianides, Christopher A., Oshabaheebwa, Solomon, Little, Jane A., Suster, Michael A., Mohseni, Pedram, Gurkan, Umut A.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 02.11.2023

Introduction: Sickle cell disease (SCD) is a common genetic red blood cell (RBC) disorder that results from a single substitution of valine for glutamic acid in the β-globin gene, resulting in sickle hemoglobin (HbSS). Under hypoxia, HbS polymerizes and forms fibers within the RBCs, thus making the...